All
FDA Approves Truqap Plus Hormone Thearpy for Some With HR-Positive, HER-Negative Breast Cancer
November 16th 2023Truqap (capivasertib) with fulvestrant has been approved for the treatment of adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, the FDA announced.